Literature DB >> 9222235

Uveitis associated with an epidemic outbreak of leptospirosis.

S R Rathinam1, S Rathnam, S Selvaraj, D Dean, R A Nozik, P Namperumalsamy.   

Abstract

PURPOSE: To define uveitis associated with leptospirosis in a clinical setting.
METHODS: We present the clinical features of 73 consecutive cases of uveitis linked clinically to an outbreak of systemic leptospirosis in patients with antibodies to Leptospira species who were examined from January to September 1994.
RESULTS: In 73 patients, the pattern of ocular involvement was unilateral in 35 and bilateral in 38. Panuveitis was seen in 106 eyes (95.5%), retinal periphlebitis in 57 eyes (51.4%), and hypopyon in 14 eyes (12.6%). Anterior uveitis alone without hypopyon was observed in three eyes (2.7%), whereas vitreous inflammatory reaction alone was seen in two eyes (1.8%). Sixty of 73 patients (82.2%) or 91 of 111 eyes (82.0%) were followed up for 8 months. Final visual acuity was 6/6 (20/20) in 47 eyes (52%) and improved during treatment, although not up to 6/6, in 15 eyes (16%). Twenty-eight eyes (31%) maintained same vision, and one eye showed deterioration of vision.
CONCLUSION: Uveitis associated with leptospirosis may manifest as unilateral or bilateral uveitis, anterior uveitis, or panuveitis. The prognosis is generally good in this entity, even when the inflammation is severe. Awareness of this disease in endemic areas is important in order to differentiate it from other uveitic entities, especially in young male patients in whom other immunologic uveitides are also common.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9222235     DOI: 10.1016/s0002-9394(14)71646-0

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  23 in total

Review 1.  Leptospirosis.

Authors:  P N Levett
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

2.  Hypertensive iridocyclitis.

Authors:  E C Kim; T P Margolis
Journal:  Br J Ophthalmol       Date:  2006-07       Impact factor: 4.638

3.  LruA and LruB antibodies in sera of humans with leptospiral uveitis.

Authors:  Ashutosh Verma; S R Rathinam; C Gowri Priya; V R Muthukkaruppan; Brian Stevenson; John F Timoney
Journal:  Clin Vaccine Immunol       Date:  2008-04-09

4.  Outpatient follow-up of patients hospitalized for acute leptospirosis.

Authors:  Anne Spichler; Daniel Athanazio; Antonio C Seguro; Joseph M Vinetz
Journal:  Int J Infect Dis       Date:  2011-05-25       Impact factor: 3.623

5.  Rapid maturation of unilateral cataract in leptospirosis.

Authors:  S R Rathinam; Shanthi Rathakrishnan
Journal:  Indian J Ophthalmol       Date:  2020-09       Impact factor: 1.848

6.  Cloning and molecular characterization of an immunogenic LigA protein of Leptospira interrogans.

Authors:  Raghavan U M Palaniappan; Yung-Fu Chang; S S D Jusuf; S Artiushin; John F Timoney; Sean P McDonough; Steve C Barr; Thomas J Divers; Kenneth W Simpson; Patrick L McDonough; Hussni O Mohammed
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

7.  Spirochetal uveitis: Spectrum of clinical manifestations, diagnostic and therapeutic approach, final outcome and epidemiological data.

Authors:  Dimitrios Kalogeropoulos; Ioannis Asproudis; Maria Stefaniotou; Marilita Moschos; Constantina Gartzonika; Ioannis Bassukas; Spiros Konitsiotis; Haralampos Milionis; Georgios Gaitanis; Konstantinos Malamos; Chris Kalogeropoulos
Journal:  Int Ophthalmol       Date:  2021-07-23       Impact factor: 2.031

Review 8.  Leptospirosis: an emerging global public health problem.

Authors:  P Vijayachari; A P Sugunan; A N Shriram
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

9.  Host-inducible immunogenic sphingomyelinase-like protein, Lk73.5, of Leptospira interrogans.

Authors:  S Artiushin; J F Timoney; J Nally; A Verma
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

10.  The C-terminal variable domain of LigB from Leptospira mediates binding to fibronectin.

Authors:  Yi-Pin Lin; Yung-Fu Chang
Journal:  J Vet Sci       Date:  2008-06       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.